Roland Goode, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Boston Scientific at 35.9% of the total. Reporting peaked in 2021 at $327 and has fallen 89.0% since, to $36 in 2025. That places this record below the midpoint for urology clinicians in NV, where the typical reported total is $2,990.
Across 43 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$313
- AbbVie$261
- Endo Pharmaceuticals Inc.$56
- Procept Biorobotics Corporation$53
- Astellas Pharma US Inc$52
- Urogen Pharma, Inc.$48
- plus $90 from 5 others
What the payments were for
- Food & beverage$81593%
- Education$577%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $313 |
| AbbVie(2 entities) | 13 | $261 |
| Endo Pharmaceuticals Inc. | 3 | $56 |
| Procept Biorobotics Corporation | 1 | $53 |
| Astellas Pharma US Inc | 1 | $52 |
| Urogen Pharma, Inc. | 3 | $48 |
| Ambu Inc. | 1 | $30 |
| Accord Healthcare, Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Endo USA, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 4 | $5 |
How this compares
$873 in reported general payments places this provider in the 20th percentile of 63 urology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 26 | $345,457 |
| MyrbetriqMirabegron | 144 | $127,236 |
| GemtesaVibegron | 18 | $18,993 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 90 | $9,536 |
| Tamsulosin Hcl | 442 | $9,496 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 284 | $7,402 |
| XyostedTestosterone Enanthate | 12 | $7,157 |
| Mirabegron ErMirabegron | 11 | $6,436 |
| Testosterone | 35 | $4,744 |
| Tadalafil | 68 | $4,211 |
| Potassium Citrate ErPotassium Citrate | 24 | $2,599 |
| Methenamine Hippurate | 20 | $2,360 |
| Finasteride | 145 | $2,106 |
| Oxybutynin Chloride ErOxybutynin Chloride | 74 | $1,837 |
| Testosterone Cypionate | 29 | $1,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $56 | $345,45726 claims |
| Astellas Pharma US IncMyrbetriq | $52 | $127,236144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 63 urology providers in Nevada.
Other urology in Reno
- Christopher EvansReno$184K
- Eric KimReno$24K
- Nicholas HauserReno$12K
- Angelo KanellosReno$11K
- Timothy SuttleReno$8K
- Ross AndersonReno$7K
- Matthew McCormackReno$3K
- Chloe ShenkReno$3K
- Christopher TamReno$3K
- Dielle DuvalReno$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.